References
- BennettJLStuveOUpdate on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implicationsClin Neuropharmacol20093212113219483479
- McDonaldWIRelapse, remission, and progression in multiple sclerosisN Engl J Med20003431486148711078776
- MurrayTJDiagnosis and treatment of multiple sclerosisBMJ200633252552716513709
- CompstonAConfavreuxCLassmannHMcAlpine’s Multiple Sclerosis4th edPhiladelphia, PAChurchill Livingstone2006
- ConfavreuxCVukusicSMoreauTAdeleinePRelapses and progression of disability in multiple sclerosisN Engl J Med20003431430143811078767
- WeinshenkerBGBassBRiceGPThe natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disabilityBrain1989112Pt 11331462917275
- World Health OrganizationAdherence to long-term therapies: evidence for action Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/index.htmlAccessed August 21, 2011
- LugaresiAAddressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivationExpert Opin Drug Deliv20096995100219637982
- TreadawayKCutterGSalterAFactors that influence adherence with disease-modifying therapy in MSJ Neurol200925656857619444532
- HalpernRAgarwalSDembekCBortonLLopez-BresnahanMComparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysisPatient Prefer Adherence20115738421423591
- TanHCaiQAgarwalSStephensonJJKamatSImpact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosisAdv Ther201128516121153000
- Al-SabbaghABennetRKozmaCMeleticheDMedication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care databaseJ Neurol2008255Suppl 2S79
- UitdehaagBConstantinescuCCornelissePImpact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up studyTher Adv Neurol Disord2011431421339904
- TremlettHLOgerJInterrupted therapy: stopping and switching of the beta-interferons prescribed for MSNeurology20036155155412939437
- O’RourkeKEHutchinsonMStopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patternsMult Scler200511465015732266
- Multiple Sclerosis International FederationAtlas of MS Database2007 Available from: http://www.atlasofms.org/query.aspx?pq=yes&s=1&q=3&r=Global&year=2007Accessed August 21, 2011
- TremlettHVander MeiIPittasFAdherence to the immuno-modulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing dosesPharmacoepidemiol Drug Saf20081756557618395883
- Multiple Sclerosis International FederationMS: the Guide to Treatment and Management2008 Available from: http://www.msif.org/en/resources/msif_resources/msif_publications/ms_the_guide_to_treatment_and_management/treatments_affecting_longterm_course_of_disease/index.htmlAccessed August 21, 2011
- PortaccioEZipoliVSiracusaGSorbiSAmatoMPLong-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosisEur Neurol20085913113518057899
- RiJPorcelJTellezNFactors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosisMult Scler20051130630915957512
- OsterbergLBlaschkeTAdherence to medicationN Engl J Med200535348749716079372